Do hydroxychloroquine (Plaquenil) interact with fluconazole (Diflucan) and nitrofurantoin (Macrobid)?

Yes, there are clinically significant interactions between Plaquenil (hydroxychloroquine), Diflucan (fluconazole), and Macrobid (nitrofurantoin)

The primary concern when combining hydroxychloroquine with fluconazole is additive QT prolongation, which increases the risk of life-threatening cardiac arrhythmias including torsade de pointes. If this combination must be used, obtain a baseline ECG and monitor closely for QT prolongation, particularly if the QTc exceeds 500 ms or increases by >60-70 ms 1, 2.

Key Drug Interactions

Hydroxychloroquine + Fluconazole: Cardiac Risk

Both drugs independently prolong the QT interval, and their combination creates additive cardiotoxicity risk 2:

• Hydroxychloroquine carries inherent risk of QT prolongation and torsade de pointes 2
• Fluconazole causes QT prolongation via inhibition of Rectifier Potassium Channel current (Ikr) 3
• Women, elderly patients, and those with structural heart disease face higher risk 1

Critical monitoring requirements:

• Baseline ECG before initiating combination
• Check electrolytes (potassium, magnesium) - hypokalemia dramatically increases arrhythmia risk 1, 2
• Monitor ECG if QTc approaches 500 ms or increases >60 ms from baseline 1
• Consider alternative antibiotics (penicillins, cephalosporins) or antifungals when possible 1

Hydroxychloroquine + Nitrofurantoin: Potential Toxicity Enhancement

While direct pharmacokinetic interactions are limited, there are concerning safety signals:

• A case report documented combined pulmonary and hepatic toxicity when fluconazole was added to chronic nitrofurantoin therapy 4
• Hydroxychloroquine is a weak CYP2D6 and P-glycoprotein inhibitor 2, 5
• Both drugs can cause hepatotoxicity independently 4
• Hydroxychloroquine increases peripheral neuropathy risk, which may be additive with nitrofurantoin's neurotoxic effects 2

Fluconazole + Nitrofurantoin: Documented Toxicity

This combination has documented evidence of precipitating serious adverse events 4:

• A published case showed fluconazole triggered combined hepatic and pulmonary toxicity in a patient on chronic nitrofurantoin
• Hepatic enzymes elevated 5× upper limit of normal
• Bilateral pulmonary disease developed
• Mechanism may involve pharmacokinetic changes induced by fluconazole affecting nitrofurantoin levels 4

Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor, plus a strong CYP2C19 inhibitor 3. While nitrofurantoin's metabolism doesn't primarily involve these pathways, the documented case suggests potential interaction mechanisms warrant caution.

Pharmacokinetic Considerations

Fluconazole's enzyme inhibition persists 4-5 days after discontinuation due to its long half-life 3. This means:

• Drug interactions continue even after stopping fluconazole
• Careful monitoring needed during this washout period
• Consider this when sequencing therapies

Hydroxychloroquine has minimal transporter interactions 5:

• Not a significant inhibitor of BCRP or OATPs
• Inhibits P-glycoprotein only at concentrations >10 µM
• Does not induce PXR or AhR-regulated genes

Clinical Management Algorithm

If all three drugs are absolutely necessary:

1. Obtain baseline ECG and electrolytes before starting combination
2. Correct any electrolyte abnormalities (especially potassium <4.0 mEq/L, magnesium <2.0 mg/dL)
3. Monitor ECG within 2-3 days of starting combination therapy
4. Check hepatic enzymes at baseline and 2 weeks after starting
5. Discontinue immediately if:
   • QTc >500 ms or increases >60 ms from baseline
   • New respiratory symptoms develop (dyspnea, cough, pleuritic pain)
   • Hepatic enzymes rise >3× upper limit of normal
   • Patient develops syncope or palpitations

Safer alternatives to consider:

• For fungal infections: Consider non-azole antifungals if appropriate for the indication
• For UTI: Consider alternative antibiotics (trimethoprim-sulfamethoxazole, fosfomycin, or beta-lactams based on susceptibility) 1
• Avoid this triple combination unless absolutely medically necessary

Special Populations at Higher Risk

Increased vigilance required for:

• Women (3.83× higher retinopathy risk with hydroxychloroquine, higher QT risk) 1, 6
• Elderly patients (>65 years) 1
• Renal impairment (affects both fluconazole and nitrofurantoin clearance) 3
• Pre-existing cardiac disease or heart failure 1, 3
• Concurrent diuretic use (hypokalemia risk) 1
• Patients on other QT-prolonging medications 1, 2

Common Pitfalls to Avoid

• Don't assume the combination is safe just because each drug is commonly used individually - the additive cardiac and hepatic risks are real 1, 2, 4
• Don't forget to check electrolytes - hypokalemia is the most modifiable risk factor for torsade de pointes 1, 2
• Don't rely solely on symptoms - QT prolongation is often asymptomatic until a fatal arrhythmia occurs 1
• Don't continue nitrofurantoin chronically without periodic monitoring - the case report involved 5 years of continuous use 4